NAS
PTCT icon

Nykredit A/S’s PTC Therapeutics PTCT Stock Holding History

Nykredit A/S’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$263K Buy
+3,225
New +$233K ﹤0.01% 929

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nykredit A/S's PTCT Position: Q2 2026 in Review

Nykredit A/S opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 3,225 shares worth $263K. The stake represents ﹤0.01% of the portfolio and ranks #929 among its holdings.

276 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Nykredit A/S held 3,225 shares of PTC Therapeutics worth $263K as of Q2 2026.
  • PTC Therapeutics was a new Nykredit A/S position in Q2 2026.
  • PTC Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #929 holding.
  • 276 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.